2622 A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC). (September 2015) - McDermott, D.F.; Infante, J.R.; Chowdhury, S.; Voss, M.H.; Motzer, R.J.; Perini, R.F.; Morosky, A.; Zheng, F.F.; White, B.C.; Wang, Q.; Jewell, R.C.; Rini, B.I.